Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana, 47907, USA.
Teva Pharmaceuticals, 145 Brandywine Pkwy, West Chester, Pennsylvania, 19380, USA.
Pharm Res. 2018 Jan 8;35(2):28. doi: 10.1007/s11095-017-2334-9.
Inhalation therapy is popular to treat lower respiratory tract infections. Azithromycin is effective against some bacteria that cause respiratory tract infections; but it has poor water solubility that may limit its efficacy when administrated as inhalation therapy. In this study, dry powder inhaler formulations were developed by co-spray drying azithromycin with L-leucine with a purpose to improve dissolution.
The produced powder formulations were characterized regarding particle size, morphology, surface composition and in-vitro aerosolization performance. Effects of L-leucine on the solubility and in-vitro dissolution of azithromycin were also evaluated.
The spray dried azithromycin alone formulation exhibited a satisfactory aerosol performance with a fine particle fraction (FPF) of 62.5 ± 4.1%. Addition of L-leucine in the formulation resulted in no significant change in particle morphology and FPF, which can be attributed to enrichment of azithromycin on the surfaces of composite particles. Importantly, compared with the spray-dried amorphous azithromycin alone powder, the co-spray dried powder formulations of azithromycin and L-leucine demonstrated a substantially enhanced in-vitro dissolution rate. Such enhanced dissolution of azithromycin could be attributed to the formation of composite system and the acidic microenvironment around azithromycin molecules created by the dissolution of acidic L-leucine in the co-spray dried powder. Fourier transform infrared spectroscopic data showed intermolecular interactions between azithromycin and L-leucine in the co-spray dried formulations.
We developed the dry powder formulations with satisfactory aerosol performance and enhanced dissolution for a poorly water soluble weak base, azithromycin, by co-spray drying with an amino acid, L-leucine.
吸入疗法常用于治疗下呼吸道感染。阿奇霉素对引起呼吸道感染的部分细菌有效,但由于其水溶性差,当作为吸入疗法给药时可能会限制其疗效。本研究通过喷雾干燥法将阿奇霉素与 L-亮氨酸共喷雾干燥,以提高其溶解度,从而开发出干粉吸入剂配方。
对所制备的粉末制剂进行粒径、形态、表面组成和体外雾化性能的特征描述。还评估了 L-亮氨酸对阿奇霉素溶解度和体外溶解的影响。
单独喷雾干燥的阿奇霉素制剂表现出良好的雾化性能,其微细颗粒分数(FPF)为 62.5±4.1%。在配方中加入 L-亮氨酸不会导致颗粒形态和 FPF 发生显著变化,这可归因于阿奇霉素在复合颗粒表面的富集。重要的是,与单独喷雾干燥的无定形阿奇霉素粉末相比,阿奇霉素和 L-亮氨酸的共喷雾干燥粉末制剂表现出明显提高的体外溶解速率。阿奇霉素的这种溶解增强可归因于复合体系的形成以及在共喷雾干燥粉末中酸性 L-亮氨酸溶解所产生的阿奇霉素分子周围的酸性微环境。傅里叶变换红外光谱数据表明,共喷雾干燥制剂中阿奇霉素和 L-亮氨酸之间存在分子间相互作用。
我们通过喷雾干燥法将氨基酸 L-亮氨酸与阿奇霉素共喷雾干燥,开发出具有良好雾化性能和增强溶解度的干粉制剂,用于改善水溶性差的弱碱性阿奇霉素。